<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762811</url>
  </required_header>
  <id_info>
    <org_study_id>CPR-00002</org_study_id>
    <nct_id>NCT03762811</nct_id>
  </id_info>
  <brief_title>Post-Market Clinical Investigation of NanoFUSE® Bioactive Matrix</brief_title>
  <official_title>Post-Market Clinical Investigation of NanoFUSE® Bioactive Matrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoFUSE Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoFUSE Biologics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to determine fusion rates and compare clinical outcomes of the&#xD;
      NanoFUSE® Bioactive Matrix during post-market clinical use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NanoFUSE® is indicated to be placed into bony voids or gaps of the skeletal system that are&#xD;
      not intrinsic to the stability of the bony structure (i.e. the posterolateral spine and&#xD;
      pelvis). These defects may be surgically created osseous defects or osseous defects created&#xD;
      from traumatic injury to bone. NanoFUSE® must be used with autograft as a bone graft extender&#xD;
      in the posterolateral spine and pelvis. This product provides a bone graft substitute that&#xD;
      remodels into the recipient's skeletal system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Success that indicates patient achieving fused or probably fused status.</measure>
    <time_frame>12 months</time_frame>
    <description>at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall patient success</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>Overall patient success will be based on all clinical and radiographic evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bone; Degeneration</condition>
  <arm_group>
    <arm_group_label>NanoFUSE® PMCF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NanoFUSE® Bioactive Matrix</intervention_name>
    <description>NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.</description>
    <arm_group_label>NanoFUSE® PMCF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Skeletally mature&#xD;
&#xD;
          -  Medically suitable for surgical management and the use of NanoFUSE® Bioactive Matrix&#xD;
             consistent with product labeling&#xD;
&#xD;
          -  Psychosocially, mentally, and physically able to fully comply with the protocol,&#xD;
             including the post-operative regimen, requires follow-up visits, filling out required&#xD;
             forms, and the ability to understand and give written informed consent&#xD;
&#xD;
          -  Retrospective data collection must be allowed by the IRB and all information&#xD;
             deidentified&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous fusion surgery of the proposed site&#xD;
&#xD;
          -  Use of chronic medications known to affect the skeleton (e.g. glucocorticoid usage &gt;&#xD;
             10mg/day)&#xD;
&#xD;
          -  Pregnant or female intending to become pregnant during this study period&#xD;
&#xD;
          -  Obesity (BMI &gt;40kg/m2)&#xD;
&#xD;
          -  Systemic infection or infection at the surgical site&#xD;
&#xD;
          -  Current or past substance abuse&#xD;
&#xD;
          -  Poor general healthy or any concurrent disease process that would place the patient in&#xD;
             excessive risk to surgery (e.g. significant circulatory or pulmonary problems, cardiac&#xD;
             disease&#xD;
&#xD;
          -  Medical condition that would interfere with post-operative assessments and care&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Holly Cole</last_name>
    <phone>978-358-7307</phone>
    <phone_ext>1004</phone_ext>
    <email>hollycole@rqmis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley Lyons</last_name>
    <phone>978-358-7307</phone>
    <phone_ext>1005</phone_ext>
    <email>ashleylyons@rqmis.com</email>
  </overall_contact_backup>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>November 30, 2018</last_update_submitted>
  <last_update_submitted_qc>November 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Demineralized Bone Matrix</keyword>
  <keyword>Bone Graft</keyword>
  <keyword>Fusion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

